ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Astellas Pharma, Inc. ?
1
High Management Efficiency with a high ROE of 6.28%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.73
3
With a growth in Net Sales of 10.4%, the company declared Outstanding results in Dec 25
- OPERATING CASH FLOW(Y) Highest at JPY 463,969 MM
- ROCE(HY) Highest at 19.83%
- INTEREST COVERAGE RATIO(Q) Highest at 7,107.07
4
With ROE of 3.35%, it has a very attractive valuation with a 1.67 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 69.23%, its profits have risen by 293.2% ; the PEG ratio of the company is 0.2
- At the current price, the company has a high dividend yield of 0
5
Majority shareholders : FIIs
6
Market Beating Performance
- The stock has generated a return of 69.23% in the last 1 year, much higher than market (Japan Nikkei 225) returns of 38.94%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Astellas Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Astellas Pharma, Inc. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Astellas Pharma, Inc.
69.23%
506.65
29.45%
Japan Nikkei 225
38.94%
1.38
28.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.01%
EBIT Growth (5y)
-2.04%
EBIT to Interest (avg)
42.73
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.42
Sales to Capital Employed (avg)
0.73
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
261.05%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
15.78%
ROE (avg)
6.28%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
50
Industry P/E
Price to Book Value
1.67
EV to EBIT
12.39
EV to EBITDA
6.97
EV to Capital Employed
1.47
EV to Sales
1.66
PEG Ratio
0.17
Dividend Yield
0.04%
ROCE (Latest)
11.86%
ROE (Latest)
3.35%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at JPY 463,969 MM
ROCE(HY)
Highest at 19.83%
INTEREST COVERAGE RATIO(Q)
Highest at 7,107.07
PRE-TAX PROFIT(Q)
Highest at JPY 134,002 MM
RAW MATERIAL COST(Y)
Fallen by 0.42% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 26.71 %
NET SALES(Q)
Highest at JPY 571,206 MM
OPERATING PROFIT(Q)
Highest at JPY 173,839 MM
NET PROFIT(Q)
Highest at JPY 100,323 MM
EPS(Q)
Highest at JPY 55.85
-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.7 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.84 times
Here's what is working for Astellas Pharma, Inc.
Interest Coverage Ratio
Highest at 7,107.07
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Pre-Tax Profit
Highest at JPY 134,002 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Pre-Tax Profit
At JPY 134,002 MM has Grown at 215.23%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 100,323 MM has Grown at 202.73%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Operating Cash Flow
Highest at JPY 463,969 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (JPY MM)
Net Sales
Highest at JPY 571,206 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 173,839 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Net Profit
Highest at JPY 100,323 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 55.85
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Debt-Equity Ratio
Lowest at 26.71 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0.42% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Astellas Pharma, Inc.
Inventory Turnover Ratio
Lowest at 1.7 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 2.84 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
